Graphene-based sensors being developed to detect disease

Graphene-based sensors being developed to detect disease
  ADELAIDE – Based in Adelaide, South Australia, Sparc Technologies Limited has partnered with the University of Adelaide to develop non-invasive sensing devices to detect disease in humans and animals. Sparc’s new graphene biomedical division will research graphene-based sensing devices used to detect volatile organic compounds (VOCs). VOCs are understood to be indicators of disease and are present in exhaled... Read More

Relay Medical and Glow LifeTech report on successful phase II clinical results for COVID-19 treatment

Relay Medical and Glow LifeTech report on successful phase II clinical results for COVID-19 treatment
  TORONTO – Relay Medical Corp. (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2), a developer of MedTech innovation, and Glow LifeTech Ltd. a private company in which Relay holds a significant equity interest, today reported on developments related to Glow’s MyCell Technology™. Glow LifeTech partner Swiss Pharmacan AG, and MGC Pharma have announced the full results of Phase II double-blind, placebo-controlled... Read More

Largo Resources mulls listing in U.S., shares up 12%

Largo Resources mulls listing in U.S., shares up 12%
  TORONTO – Largo Resources Ltd.  said Thursday January 14 that it is considering a potential listing of its shares in the U.S. with a view to increasing its access to U.S. capital markets. The move comes as the company continues to develop its recently-launched Largo Clean Energy division into an industry-leading, vertically integrated redox flow battery business.... Read More

Pure Extracts outlines study on psilocybin oral tablets, capsules and nasal gel

Pure Extracts outlines study on psilocybin oral tablets, capsules and nasal gel
VANCOUVER – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) a plant-based extraction company, reported that it has delineated the timetable and milestones for its study on the formulation and manufacturing of psilocybin based active treatments for oral tablets, capsules and a nasal gel that will be used as an investigational product. The study with be conducted at... Read More

PlantX Announces Monthly Gross Revenue of $1,029,883 for December 2020

PlantX Announces Monthly Gross Revenue of $1,029,883 for December 2020
VANCOUVER – PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) reported that it achieved record monthly gross revenue of $1,029,883 for the month of December 2020. For the month of November 2020, the Company achieved gross revenue of approximately $640,000. The Company attributes the increased revenue between November and December to the exceptional branding, marketing and partnerships that the... Read More